---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009986"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-03-13T23:59:59+00:00"
generated_at: "2026-05-15T12:37:54.950821+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# bioAffinity 2025 revenue $6.2M; CyPath Lung revenue up 87% YoY, net loss $14.9M

## Summary
- Total revenue $6.2M, down 34% from $9.4M in 2024 due to discontinuing unprofitable pathology services.
- CyPath Lung revenue increased 87% YoY; tests performed up 99%, physician orders up 67%.
- Net loss $14.9M vs $9.0M in 2024, driven by warrant fair value changes and higher commercialization costs.
- Cash $6.5M at year-end; raised $16.9M in equity in 2025. Guidance: >100% CyPath Lung unit sales growth in 2026.
- Appointed Gordon Downie MD PhD as CMO; Roberto Rios CPA and John Oppenheimer MD to board of directors.

## SEC filing metadata
- accession: 0001493152-26-009986
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226009986/0001493152-26-009986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226009986/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009986
- JSON: https://secwatch.observer/filing/0001493152-26-009986.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.